Folic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease
Open Access
- 1 March 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 6 (3), 482-488
- https://doi.org/10.2215/cjn.05310610
Abstract
Background and objectives The efficacy of folic acid therapy to lower homocysteine (Hcy) levels in an effort to reduce cardiovascular disease (CVD) risk in patients with ESRD or advanced chronic kidney disease (ACKD; creatinine clearance, 24 months (RR, 0.84; 95% CI, 0.72 to 0.98; P = 0.02), a decrease in Hcy level >20% (RR, 0.83; 95% CI, 0.73 to 0.95; P = 0.007), and no or partial folic acid fortification (RR, 0.80; 95% CI, 0.65 to 0.99; P = 0.04). The beneficial effect also was seen when Hcy levels decreased >20%, even in the presence of folic acid fortification (RR, 0.85; 95% CI, 0.73 to 0.99; P = 0.04). In the corresponding comparison groups, the estimated RRs were attenuated and insignificant. Conclusions Folic acid therapy can reduce CVD risk in patients with ESRD/ACKD by 15%. A greater beneficial effect was observed among those trials with no or partial folic acid fortification or a decrease in Hcy level >20% regardless of folic acid fortification.This publication has 23 references indexed in Scilit:
- B Vitamins and the Risk of Total Mortality and Cardiovascular Disease in End-Stage Renal DiseaseCirculation, 2010
- Homocysteine as a Risk Factor for Cardiovascular Disease in Patients Treated by Dialysis: A Meta–analysisAmerican Journal of Kidney Diseases, 2009
- Cardiovascular disease in patients with chronic kidney diseaseVascular Health and Risk Management, 2009
- Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) TrialAmerican Journal of Kidney Diseases, 2009
- Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular eventsHemodialysis International, 2007
- The Interpretation of Random-Effects Meta-Analysis in Decision ModelsMedical Decision Making, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004
- Elevated Plasma Homocysteine Was Associated With Hemorrhagic and Ischemic Stroke, but Methylenetetrahydrofolate Reductase Gene C677T Polymorphism Was a Risk Factor for Thrombotic StrokeStroke, 2003
- The Effect of Folic Acid Fortification on Plasma Folate and Total Homocysteine ConcentrationsThe New England Journal of Medicine, 1999
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986